Biostar Pharmaceuticals, Inc. to Present at the Brean Murray, Carret & Co. China Growth Conference
Mr. Ronghua Wang, Chief Executive Officer and Ms. Elaine Zhao, ChiefFinancial Officer, are scheduled to present at 11:20 am ET on ThursdayNovember 19 and are available to host one-on-one meetings with conferenceattendees throughout the one-day event. Mr. Wang and Ms. Zhao will discuss theCompany's products including Biostar's leading hepatitis B medicine, XinAoxing, the Company's expansion into rural networks in China, financialresults, and the Company's long-term growth strategies.
Registration is mandatory. For more information on the conference, contactyour Brean Murray, Carret & Co. representative. To register please visit orcontact Lindsay Zuckerman at 212-702-6577 or via email atLindsay.Zuckerman@bmur.com.
About Biostar Pharmaceuticals, Inc.
Biostar Pharmaceuticals, Inc., through its wholly-owned subsidiary inChina, develops, manufactures and markets pharmaceutical and medical nutrientproducts for a variety of diseases and conditions. The Company's most popularproduct is its Xin Ao Xing Oleanolic Acid Capsule, an over-the-counter ("OTC")medicine for chronic hepatitis B, a disease affecting approximately 10% of theChinese population. In addition to its hepatitis product, Biostar manufacturestwo broad-based OTC products, two prescription-based pharmaceuticals and tennutrients. The Company has adopted international standards and is in theprocess of applying for two patents.
Certain statements in this release concerning our future growth prospectsare forward-looking statements, within the meaning of Section 27A of the U.S.Securities Act of 1933, as amended, and Section 21E of the U.S. SecuritiesExchange Act of 1934, as amended, which involve a number of risks anduncertainties that could cause actual results to differ materially from thosein such forward-looking statements. The risks and uncertainties relating tothese statements include, but are not limited to, risks and uncertaintiesregarding the success of our investments, risks and uncertainties regardingfluctuations in earnings, our ability to sustain our previous levels ofprofitability including on account of our ability to manage growth, intensecompetition, wage increases in China, our ability to attract and retain highlyskilled professionals, time and cost overruns on fixed-price, fixed-time framecontracts, client concentration, our ability to successfully complete andintegrate potential acquisitions, withdrawal of governmental fiscal incentives,political instability and regional conflicts and legal restrictions on raisingcapital or acquiring companies outside China. Additional risks that couldaffect our future operating results are more fully described in our UnitedStates Securities and Exchange Commission filings including our S-1 dated June27, 2008, our Quarterly Report on Form 10-Q for the quarter ended June 30,2009, our 10-K for the year ended December 31, 2008, and other recent filings.These filings are available at http://www.sec.gov. We may, from time to time,make additional written and oral forward-looking statements, includingstatements contained in our filings with the Securities and ExchangeCommission and our reports to shareholders. We do not undertake to update anyforward-looking statements that may be made from time to time by or on ourbehalf.For further information, contact: Ms. Elaine Zhao, CFO Tel: +1-626-456-2789 Email: firstname.lastname@example.org John Mattio HC International, Inc. Tel: +1-914-669-5340 Email: email@example.com Web: http://www.hcinternational.net
SOURCE Biostar Pharmaceuticals, Inc.
You May Also Like